Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and sign a consent form
• Adults aged 18 to 75, of any gender
• People who have been diagnosed (confirmed by tissue testing) with certain types of B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma, or related types — and whose cancer has come back or stopped responding to previous treatments (specific treatment history requirements vary by lymphoma type — confirm with trial site)
• People who have at least one measurable area of disease that is 1.5 cm or larger
• People whose life expectancy, apart from their lymphoma, is estimated to be more than 12 weeks
• People whose lymphoma has previously tested positive for CD19 or CD70 markers
• People with a general health and activity level score (called ECOG status) of 0 to 3, meaning they range from fully active to limited in self-care (confirm with trial site)
• People whose liver, kidney, heart, and blood counts meet specific minimum levels of function as determined by blood tests and heart scans
• People who have previously had one autologous stem cell transplant (a procedure using their own stem cells)
• People who have waited the required time since their last treatment before receiving the study cell infusion (at least 3 weeks after chemotherapy or immunotherapy, or at least 2 weeks after targeted drug therapy alone)
• People whose previous CAR-T therapy has failed or whose disease came back at the 3-month assessment point
• People of childbearing or child-fathering potential who are willing to use birth control throughout the study, and women who can become pregnant must have a negative pregnancy test
• People who have tested negative for COVID-19 on two separate PCR or nucleic acid tests

Who may not be able to join:

• People who are allergic to any ingredient in the study cell product
• People who have had, or currently have, another type of cancer
• People who developed moderate to severe graft-versus-host disease (a complication from transplant) after a previous stem cell transplant, or who are still receiving treatment for it
• People who have had systemic gene therapy within the past 3 months
• People with an active, serious infection involving fungal, viral, or bacterial causes (though preventive infection treatments are permitted)
• People with a known history of hepatitis B (with certain virus levels), hepatitis C, syphilis, HIV, or other immune deficiency conditions
• People with severe heart failure classified as Class III or IV by standard medical criteria
• People still experiencing significant side effects (above a minor level) from previous treatments, with the exception of hair loss, tiredness, or reduced appetite
• People with a known history of active seizures, ongoing seizure activity, or other diseases affecting the brain or nervous system
• People whose scans (CT or MRI) show lymphoma affecting the brain or spinal fluid
• People who are currently breastfeeding
• People who, in the opinion of the trial doctor, have any other circumstances that could increase risk or affect the reliability of the study results

Important: Always verify eligibility with the trial site directly before applying.